Revenue Update on CorMedix(NYSEMKT:CRMD)

CorMedix(NYSEMKT:CRMD) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during Pre-market on Aug 5, 2016. Earnings per share were $-0.13.

CorMedix (CRMD) shares turned negative on Wednesdays trading session with the shares closing down -0.05 points or -2.79% at a volume of 3,35,684. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $1.84. The peak price level was also seen at $1.84 while the days lowest was $1.65. Finally the shares closed at $1.74. The 52-week high of the shares is $4.54 while the 52-week low is $1.15. According to the latest information available, the market cap of the company is $67 M.

Several Insider Transactions has been reported to the SEC. On Jun 29, 2016, Janet Dillione (director) purchased 3,738 shares at $2.67 per share price.Also, On Jun 22, 2016, Antony Pfaffle (Interim Chief Medical Officer) sold 29,657 shares at $2.15 per share price.On Jun 6, 2016, Matthew Duffy (director) sold 46,106 shares at $2.73 per share price, according to the Form-4 filing with the securities and exchange commission.

CorMedix Inc. (CorMedix) is a pharmaceutical company that in-licenses develops and commercializes prophylactic and therapeutic products for the treatment of infectious diseases in cardiac renal and oncology patients. The Company has in-licensed all of the products in its pipeline. The Company’s primary product is Neutrolin a catheter lock solution which is used the treatment of catheter-related infections and thrombosis in the central venous catheter markets such as dialysis critical care and oncology. It has the worldwide rights to develop and commercialize product candidates CRMD003 (Neutrolin) and CRMD004. The Company manufactures CRMD003 (Neutrolin) through Navinta LLC a United States-based active pharmaceutical ingredient (API) developer. The CRMD004 is the gel formulation of Neutrolin which is in the pre-clinical stage of development.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *